Member Info for jdt1990

Sorry missed a key point off that post wyndrum....I fully agree with what you've said there can't see developing govt's rolling out a testing programme instead of a vaccination programme - its the same issue just different "medium".
I was getting more at the business route where companies in developing countries who are impacted negatively as the people that work for them are locked down but they have the funds to buy tests. They would be suffering from a slow or non existent vaccination roll out to the people that work for them. Could a company funded testing programme in those countries be a potential market?

AS talked about possible production in Asia at the AGM. I feel we've all been too focused here on "the boat" for UK and developed countries.
Lets just forget about the UK and US for a second who you would think will be able to roll out a vaccination programme fairly efficiently.....what about developing/EM countries with huge populations and geographies - India / Brazil / Russia and the likes. Their vaccination programmes will be nowhere near as quick to roll out given the countires who developed the vaccines (UK/US) are taking the bulk for themselves. Then when they can get hold of them - its not going to be easy to roll out.
That's why I think testing isn't a "dead duck". Maybe the market will dwindle in the UK/US over the next few months, who knows but this is a global pandemic, plenty of the 8Bn people in the world are in less developed countries (excluding China) I think its about 3.6Bn.....they're going to need testing.

I would agree in the most part with that Infinis but two thing I would say:
1. "ultimately covid test earnings will allow more to be achieved on the therapy trials side without dilutive placing or involving a big pharma partner". Yes, but the covid earnings can't come at the expense of Avct's reputation in either division. A cr*p test would be catastrophic, so there is always the risk that in that search for the "holy grail" test. Some of the short term revenues from Covid test earning have to be given up. Which I think is why some here (including myself) put a lower weighting on the specific Covid test revenue element when evaluating future potenital. The longevity of this potential revenue stream is unknown. In theory, there could be a miracle Covid cure next week and that market is wiped out completely.
2. "As every man and his dog gets out antigen lfds it is tempting to pretend the covid doesn't matter but it is actually Avacta's springboard to a whole lot more and a very big deal indeed." Remember Covid LFT's are a great way to showcase what Affimers can do, they are the differentiator here, everything else is just a fairly bog standard plastic casing mechanism. What a lot of people forget is that actually again, this is AVCT's IP so putting in out to market for a sub standard LFT would be catastrophic for the reputation of Affimers, which as we saw last week in the RNS, are gaining traction in many other fields.
This business has to be so so so careful about how they put Affimers to use to protect the credibility, which takes time. One wrong move at its 10 steps back!

Second Page - I really did go on :)
"Precision cancer therapy, brought to you by Avacta, the same guys who delivered a cr*ppy LFT in the pandemic" just doesn't ring right to me.
Patience is needed here - as is always the case in the biomed space. But what is unique for AVCT is you have a scientist at the helm who want to put to the market only good quality products and a wide range of them too. Take away COvid, we still have unique IP in Affimers which are shown to work and a separate therapeutics division. I like that, we won't become a cheap knock off shop.
All done by a company of circa 100 employees.
And one final thing.....when trolls come on here spouting you haven't sold a test etc etc how is this Co worth 300m mkt cap.
Just take a look at Gilead's purchase of Kite pharma - Gilead paid $11.9Bn for a company that was pre revenue, loss making and significantly in debt.....not saying it will happen here but look what we have on the table, it only takes one to hit!

Sorry to hear about you experiences with this awful disease Tullaghan. I'll keep my political views to myself on the Covid related front as I could write a book on that (its easy to be an expert after the fact I suppose) but what I would say is I am also baffled as to how cancer takes a sideline, were not talking STI's and the common cold here, were talking about what has been the biggest killer for many years now!
The govt spent £520m on eat out to help out(appreciate business has to be protected BUT)......surely some of that money would be better spent as R&D grants to companies like AVCT who have potentially revolutionary advances in medicine here. AVCT had to raise £40m via a placing to progress their therapeutics work, which otherwise would have been sidelined for a long time. Maybe I am a bit of an AVCT obsessive but how can the govt spend billions on shady PPE deals but AVCTs therapeutics not get a look in for funding.
Anyhow....I ramble on with my post xmas musings.
AVCT became caught up in the Covid stock rush back in Mar/Apr. Some invested here as part of that, at all time high SP's and things haven't progressed at the pace they may have liked them to in terms of return. I get that.
However, I just cant see how this business is put in that same league as other Coid plays. There is infinitely more going on here than Covid and longer term I feel it will pay off hugely. I just depends if you are willing to wait.
I will defend AS to the hilt on how he has run this business.
- Raised £40m to progress the "bread and butter" therapeutics projects of this company at minimal discount on AIM, attracting big name institutional investors. Those II's have done their due diligence....brilliant business in my view.
- Expanded licensing deals with some of the worlds biggest pharmas (LG Chem / Daewoong). Would they do that if they saw no commercial value in Avcts products? No.
- Agreed licensing deals for Affimers in non COvid related areas - we are now get paid for people to simply use our IP, what does that tell you? No workload on AVCT's end but money through the door.
- Not once have AVCT been mentioned in the shady goings on around Covid testing i.e. poor performance, mates rates etc etc.
- The man is remunerated in options that can only be exercised once SP and performance related milestones are met. What better way to show you are incentivised at shareholders interest?

He isn't without fault. However, I feel he is mainly guilty of being naive to how slow third parties can be, especially when they are Govt related. All the Covid work, we had the affimers created months ago! He was excited about what they could do. Sorry to say that his expectations of producing a final product fell at the Cytiva/BBI/CONDOR hurdles.
What I think is great though, is he is still waiting until a top quality product that uses Affimers is available and has been through all the right channels. As I said before, look at Innova.....their reputation is shot

leewill - When you look at what AVct have been working on for years in the therapeutics space, this is their “bread and butter”, cancer is a known entity, well researched and up to this point progress has been solely in Avct’s hands, hence why we were told EOY for submission and we got it.
With regards to the COViD tests, it’s obviously a great opportunity but it’s also a completely unknown entity, a miracle cure could quite easily appear tomorrow. As an unknown entity, the goalposts are constantly being moved by regulatory boards, new strains etc etc.
I think it makes total business sense to not u-turn from your original business model to focus all attention and resources on something that is all over the place in many regards. It’s very clear delays are on third parties end, so we move along with this COViD work but not at the expense of other avenues.
Remember, this is one way to showcase affimers not the only way. It would be a shame if this never happened (I can’t see that being the case) but as a LTH I would much rather see this be done properly and come out of it yes maybe less revenue but with a solid reputation....not like Innova....what would that have done for Avcts name in the bio world?

I'll be asking to dial in and putting a few questions forward....I am sure they'll get ignored but worth a try. On first reading I thought this was a bit on a non event RNS, just a GM to approve the placing. However, I agree that when I looked over it again the "cover further possible fundraises / corporate actions" bothered me. Why put that unless you have something planned?

Definitely Richob - lets hope this gets even 10% of the fanfare a half a*rsed hurried vaccine did!

Not even 9am and the leech is back - wouldn't even give the time of day to this cretin

Mikey I think people have finally woken up and smelled the bacon.....that this company is way way more than just a Covid play. It in fact shouldn't be one at all, it was just being priced that way having been caught up in the mad rush of people herding in here back in MAr/Apr.
Finally we see the fruits of what this company has been working on for years and what a scientific breakthrough this could be for the world if it progresses well in humans.
For me, AS has delivered on his promises, further confirming the view that delays on the Covid side are all 100% down to third parties. This RNS was full under our control and boy has he delivered.
AS's credibility and integrity has never been in doubt for me, hopefully people now see this and take the "where the hell is my test" blinkers off. He is a scientist, perfectionist and believes AVCT could be a household name longer terms. Ambitious and maybe a little naive in communicating to that market maybe yet - but what is wrong with that? Surely you want someone ambitious running your business but all the way he is protecting the integrity of the business he runs.
Anyway for me, he is pushing for a promotion from Sir Al to Saint Al in the not too distant future if he continues this way.

I second that Chengdo, puts a bit of perspective on the bickering that goes on here! Glad to see an RNS that I don't think anyone argue is anything short of outstanding and Tony, I really do hope this is something that can help you fight such a terrible disease!

This is amazing news and fingers crossed there is material progress and success with this in the fight against what is a horrendous disease.
I also take great confidence that AS has hit the AVA6000 timeline of EOY as he stated he would, something which was fully in control. Shows to me, as expected, that the delays with the Covid work are very much third party related but despite that the business continues to push on in other avenues.
I have backed AS and his integrity all the way, lets hope this puts AVCT back on the map for something other than LFT's and we can really start to showcase how special this business could be!

The price of the placing is pretty good - which underpins the clear economic value/viability of the project - there is no doubt about that.
What concerns me is all the warrants that keep getting attached to these placings, there is now 1/3 of the current issued share capital in outstanding warrants which when exercised dilute further.
It also just P*sses me off that he gave Imweru away for $1m, of which we only see $200-300k in cash near term and a NSR that could be years away from generating any cash. Some really poor business decisions along the way (and big salaries) mean the balance sheet never has enough cash and the need for placing after placing. I know its part of AIM but I would imagine he wouldn't operate like this if he had a good bit of skin in the game himself!

Valuerebel - you have no idea about anyone's circumstances so would appreciate you not telling me what to do with my investments. I am bound by lengthy holding periods for compliance reasons on my holdings, so cant just sell up, move on and then come back.

This has to be the most common and stupid response to shareholders who voice disgust at the way a CEO conducts business on a BB ever!
The fundamentals of the project are very very strong. However, the man gave Imweru away for $1m plus a NSR royalty that will bear no cash flow for years - dumb business. Blyvoor has dragged on longer than anyone could ever have imagined with countless empty promises along the way. The man continues to take salaries that dilute shareholder value.
The more that goes on, the more the potential value of the projects people invested here for is eroded away.
"Just average down" and "shut up and sell up" are ridiculous comments. Some people may not have funds to average down. Other may not be able to just lock in paper losses to go try make it back elsewhere....naive comment to say the least.
I'm in here at a decent average and am about breakeven luckily (not at KIBO sadly) but am well within my rights to be disgruntled at the constant lack of anything tangible that comes from this man - and guess what, at my expense!!! None of the board here have big skin in the game so he doesn't care

Yet again LC does what he does best delivers a placing, reducing KIBO's shareholders indirect interest in what is probably the only value add project this company will ever produce...

"Following the issue of the Financing Shares and Admission, Kibo Energy plc will be interested in, in aggregate, 96,138,738 Ordinary Shares representing approximately 25.52% of the Company's then issued share capital."

Shock horror - more dilution. For crying out loud LC just get something done, revenues through the door and you wont have to keep going to the market for more money! There's also 1/3 of the company's current issue share capital in outstanding warrants to consider (albeit at an average of probably more than 2p which isn't the end of the world)!
Can't say many here didn't see this coming, it was a concern for me that the longer Blyvoor dragged on, there was always still going to be cash going out of the door to pay LC and his crooked mates plus "progress" Blyvoor and Haneti.
Raise at 2p.....this has to be the last one now and he needs to pull his finger out of his a** and get something done.
Would be nice to be bale to attend the GM and pose a few questions to him!

Absolutely spot on Neutronic. Sadly at the moment the SP is driven by and this bb has been overun by a focus on only one of those....
What happens when the LFD is CV, and sold in the millions?
And an outcry that it "hasn't happened yet" "wheres the test" "AS is a conman" blah blah blah. Well thank god it hasn't - just look at the stick Innova are rightly getting for their inadequate product.
This is all lining up nicely for AVCT and I think many will be thanking AS for his perfectionism in the not too distant future!

Hi Thebuckers - Don't think there is any need for nay name calling and your point of view is perfectly reasoned. I believe there are two ways to view the missed deadlines:
1. Naivety on AS's part that the work AVCT needed to do (i.e. produce the Affimers) was done in quick time and he simply hasn't foreseen the ridiculous heel dragging of all the third parties that have been involved in this process. (this is my view).
2. AS is either another AIM cowboy CEO misleading shareholders / he is completely out of his depth. (I have invested in enough dog shares on AIM to get a feeling he is a genuine guy just caught up in something that is much bigger than the science).
This is also the pharma business - delays, unforeseen challenges are all part of the process. He has missed timelines, no question. However, I argue AS maybe got carried away with his excitement and this was naïve not anything else.
I would agree with your timing is of the essence comment if the LFT was what this company set out to do. However, again, regardless of whether the SP is currently Covid/non COvid progress driven, the Affimer IP is the big deal here in the diagnostics space, not the LFT itself. AS needs to be very careful with what goes to market that contains Affimers. Releasing something sub standard could have dire consequences for the bigger picture.
If you're going to do something, do it right and first time round right!

Sorry let me be a little clearer on that wyndrum. I do agree that without the Covid rush, we wouldn't have got such a alrge placing away at minimal diso**** on AIM. However, you have to assume that II's have done their DD and would be aware of what the business is doing outside of that and the potential that offers longer term.
What I mean there is that the Covid angle is another opportunity for AVCT to showcase Affimers and their broad use cases across the medical industry. The potential distraction is that they hurry to get a sub standard LFT out to the market to capitalise on an opportunity with a lot of unknowns. That then ends up getting the kind of slating Innvoa tests have ended up getting. What does that do for the Affimer IP name? It kills the reputation! And therefore, in trying to please impatient PI's with pitchforks hammering his door down saying "where is our test" (which I am glad AS isn't bowing to)...you have ruined the Affimer credibility and any future collaborations.
The science here is way beyond anything many of us here can comprehend. So I think its very easy for people to criticise on a bb about timelines, but AS isn't exactly just building Lego.
Just imagine this scenario......"Your revolutionary cancer therapy, brought to you by AVCT, the makers of a shoddy LFT that didn't really work during the Covid pandemic"
Not sure that's what I invested for?